Eric J. Messika, Ph.D, MBA

During the past fifteen years, I have been extensively involved, independently and through Coronis Partners in the seeding and growth of emerging Biotech companies - from Private Equity Funding (more than $16M accumulated in eight companies), Strategy Building, Entrepreneur and Management Coaching, Business Development and Exit Strategy. Five out of the eight companies performed IPO's in TASE and the US, two of them yielded 5-10 fold return to investors. In the past two years, Coronis became a Specialty Pharma company, named Coronis Neurosciences (CNS) , developing peptide drugs for the treatment of neurocognitive and neurodegenerative disorders. CNS focuses on the treatment for a rare genetic autism named ADNP- Syndrome , encompassing global developmental delay and cognitive dysfunction in children. Our leading Drug (CP201) faces a Phase II/III pivotal clinical trials in ADNP children. Specialties: Investment Management, Entrepreneurship, Biotechnology Companies, Strategic Development,.